摘要
目的:探讨动态对比增强磁共振成像(DCE-MRI)、表观扩散系数(ADC)值联合中性粒细胞与淋巴细胞比值(NLR)、游离前列腺特异性抗原/总前列腺特异性抗原(f PSA/t PSA)诊断前列腺癌(PCa)的诊断价值。方法:选择2021年3月至2023年8月成都市第二人民医院收治的179例PCa患者作为PCa组和163例良性前列腺增生(BPH)患者作为BPH组。对比两组DCE-MRI定量参数、ADC值和外周血NLR、血清f PSA/t PSA。受试者工作特征曲线(ROC)分析各指标联合诊断PCa的价值。结果:PCa组K^(trans)、K_(ep)、NLR均高于BPH组(P<0.05),ADC、f PSA/t PSA低于BPH组(P<0.05)。各指标联合诊断PCa的曲线下面积为0.956,高于单独诊断。结论:PCa患者DCE-MRI参数K^(trans)、K_(ep)和NLR增高,ADC值和f PSA/t PSA降低,联合DCE-MRI参数、ADC值、NLR和f PSA/t PSA联合诊断PCa具有较高价值。
Objective:To investigate the diagnostic value of dynamic contrast-enhanced magnetic resonance imaging(DCE-MRI),apparent diffusion coefficient(ADC)value combined with neutrophil-to-lymphocyte ratio(NLR)and free prostate specific antigen/total prostate specific antigen(fPSA/tPSA)in the diagnosis of prostate cancer(PCa).Methods:A total of 179 PCa patients admitted to Chengdu Second People's Hospital from March 2021 to August 2023 were selected as PCa group and 163 patients with benign prostatic hyperplasia(BPH)were selected as the BPH group.The DCE-MRI quantitative parameters,ADC values and peripheral blood NLR,and serum fPSA/tPSA were compared between the two groups.The receiver operating characteristic curve(ROC)was used to analyze the value of each index for diagnosing PCa.Results:K^(trans),K_(ep) and NLR in PCa group were higher than those in BPH group(P<0.05),ADC and fPSA/tPSAwere lower than those in BPHgroup(P<0.05).The area under the curve of PCa combined diagnosis was 0.956,which was higher than for diagnosis alone.Conclusion:The DCE-MRI parameters K^(trans),K_(ep) and NLR of PCa patients increased,ADC and fPSA/tPSA decreased,The combination of DCE-MRI parameters,ADC,NLR and fPSA tPSA can improve the diagnostic value of PCa.
作者
张汉培
赖飞
郭浩
赵灿鑫
王逸敏
ZHANG Han-pei;LAI Fei;GUO Hao;ZHAO Can-xin;WANG Yi-min(Department of Urology Surgery,Chengdu Second People's Hospital,Chengdu,Sichuan,610021,China;Department of Radiology,Chengdu Second People's Hospital,Chengdu,Sichuan,610021,China;Department of Radiology,The First Affiliated Hospital of Chengdu Medical College,Chengdu,Sichuan,610500,China)
出处
《现代生物医学进展》
CAS
2024年第19期3679-3681,共3页
Progress in Modern Biomedicine
基金
四川省科技计划项目(2021YFG0316)。